U.S. markets close in 5 hours 57 minutes
  • S&P 500

    3,824.53
    -6.86 (-0.18%)
     
  • Dow 30

    30,925.72
    -42.10 (-0.14%)
     
  • Nasdaq

    11,302.56
    -19.68 (-0.17%)
     
  • Russell 2000

    1,737.95
    -3.38 (-0.19%)
     
  • Crude Oil

    98.09
    -1.41 (-1.42%)
     
  • Gold

    1,754.80
    -9.10 (-0.52%)
     
  • Silver

    19.13
    +0.01 (+0.05%)
     
  • EUR/USD

    1.0178
    -0.0092 (-0.90%)
     
  • 10-Yr Bond

    2.8050
    -0.0040 (-0.14%)
     
  • GBP/USD

    1.1902
    -0.0049 (-0.41%)
     
  • USD/JPY

    135.7740
    -0.0680 (-0.05%)
     
  • BTC-USD

    20,177.67
    +770.72 (+3.97%)
     
  • CMC Crypto 200

    436.94
    +1.42 (+0.33%)
     
  • FTSE 100

    7,138.62
    +113.15 (+1.61%)
     
  • Nikkei 225

    26,107.65
    -315.82 (-1.20%)
     

Fujifilm To Buy Cell Therapy Plant From Atara For $100M

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation, will acquire a cell therapy plant from Atara Biotherapeutics Inc (NASDAQ: ATRA) for 0 million.

  • According to the company, the 90,000-square-foot facility in Thousand Oaks, California, is "readily expandable" and has the flexibility to produce clinical and commercial treatments, including allogenic T-cell and CAR-T immunotherapies.

  • As part of the deal, Fujifilm Diosynth, will begin a long-term manufacturing agreement to help produce treatments in Atara's clinical pipeline, including tabelecleucel for Epstein-Barr virus-positive lymphoproliferative disease following a transplant.

  • Also See: Atara Bio Unveils Pivotal Data On T Cell Therapy Tabelecleucel In Transplant Patients.

  • Fujifilm said it plans to offer positions to the plant's current 140 employees. "The collective expertise of the team will further support our efforts as a world-class CDMO," Fujifilm Diosynth CEO Martin Meeson said in a statement.

  • The agreement is expected to reduce Atara's planned operating expenses.

  • Upon closing, the upfront consideration, along with the reduction in operating expenses, in addition to Atara's existing cash balance, is expected to fund Atara's planned operations into Q4 2023.

  • Price Action: ATRA shares are up 4.92% at $16.00 during the premarket session on the last check Thursday.

See more from Benzinga

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.